NCT02673567View on ClinicalTrials.gov

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 16, 2016

Study Completion Date

February 10, 2017

Conditions

Pharmacokinetics

Interventions

DRUG

TEV-48125 - 1

Subcutaneous administration Dose Regimen 1

DRUG

TEV-48125 - 2

Subcutaneous administration Dose Regimen 2

DRUG

TEV-48125 - 3

Subcutaneous administration Dose Regimen 3

DRUG

Placebo

Matching Placebo

Trial Locations (1)

91206

Teva Investigational Site 13529, Glendale

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02673567 - To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125 | Biotech Hunter | Biotech Hunter